Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma ( Schizotrypanum ) cruzi in Immunocompetent and Immunosuppressed Murine Hosts

Abstract

We have studied the in vivo activity of the new experimental triazole derivative SCH 56592 (posaconazole) against a variety of strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas' disease, in both immunocompetent and immunosuppressed murine hosts. The T. cruzi strains used in the study were previously characterized as susceptible (CL), partially resistant (Y), or highly resistant (Colombiana, SC-28, and VL-10) to the drugs currently in clinical use, nifurtimox and benznidazole. Furthermore, all strains are completely resistant to conventional antifungal azoles, such as ketoconazole. In the first study, acute infections with the CL, Y, and Colombiana strains in both normal and cyclophosphamide-immunosuppressed mice were treated orally, starting 4 days postinfection (p.i.), for 20 consecutive daily doses. The results indicated that in immunocompetent animals SCH 56592 at 20 mg/kg of body weight/day provided protection (80 to 90%) against death caused by all strains, a level comparable or superior to that provided by the optimal dose of benznidazole (100 mg/kg/day). Evaluation of parasitological cure revealed that SCH 56592 was able to cure 90 to 100% of the surviving animals infected with the CL and Y strains and 50% of those which received the benznidazole-and nifurtimox-resistant Colombiana strain. Immunosuppression markedly reduced the mean survival time of untreated mice infected with any of the strains, but this was not observed for the groups which received SCH 56592 at 20 mg/kg/day or benznidazole at 100 mg/kg/day. However, the overall cure rates were higher for animals treated with SCH 56592 than among those treated with benznidazole. The results were confirmed in a second study, using the same model but a longer (43-dose) treatment period. Finally, a model for the chronic disease in which oral treatment was started 120 days p.i. and consisted of 20 daily consecutive doses was investigated. The results showed that SCH 56592 at 20 mg/kg/day was able to induce a statistically significant increase in survival of animals infected with all strains, while benznidazole at 100 mg/kg/day was able to increase survival only in animals infected with the Colombiana strain. Moreover, the triazole was able to induce parasitological cures in 50 to 60% of surviving animals, irrespective of the infecting strain, while no cures were obtained with benznidazole. Taken together, the results demonstrate that SCH 56592 has in vivo trypanocidal activity, even against T. cruzi strains naturally resistant to nitrofurans, nitroimidazoles, and conventional antifungal azoles, and that this activity is retained to a large extent in immunosuppressed hosts.Chemotherapy of Chagas' disease (American trypanosomiasis), a parasitic disease caused by the kinetoplastid protozoan Trypanosoma (Schizotrypanum) cruzi which afflicts 16 to 18 million people in Latin America, remains an enormous scientific and social challenge, as the drugs currently available, nitrofurans (nifurtimox; Bayer) and nitroimi...

Chagas disease: What is known and what should be improved: a systemic review

“…These have not been shown to be effective in vivo, including during the acute phase of the disease. More recently, posaconazole, another azolic derivate, was shown to be very promising and is now at the clinical trial phase 44 .…”

“…Among these are allopurinol, an antiuricemic hypoxanthine that is used to treat gout, and antifungals that inhibit ergosterol, such as ketoconazole, itraconazole and fluconazole [42][43][44][45][46] . These have not been shown to be effective in vivo, including during the acute phase of the disease.…”

The effects of nitric oxide on the immune system during Trypanosoma cruzi infection

“…Studies using experimental models of acute T. cruzi infection have demonstrated that the anti-parasitic activity of benznidazole involves the participation of these cytokines (Michailowsky et al 1998, Molina et al 2000, as well as covalent modifications of macromol-ecules by nitroreducer intermediates (reductive stress). Conversely, nifurtimox acts by reducing the nitro group to unstable nitro anion radicals, which, in turn, react to produce highly toxic reduced oxygen metabolites (superoxide anion and hydrogen peroxide) (Docampo 1990).…”

Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruzi

“…In addition to blocking ergosterol production, antifungal azoles cause accu-mulation of toxic methylated sterol precursors, leading to pathogen growth arrest and cell death (16). The antiparasitic effect of antifungal azoles on TC has been observed by several investigators (17)(18)(19)(20)(21)(22); yet, only recently, the antifungal drug posaconazole, proven to be capable of producing a parasitological cure in a mouse model of the chronic stage of Chagas disease, has been reported to be entering clinical trials in June 2010 (23).…”